IL317440A - Fitusiran לטיפול בהמופיליה a ו-b - Google Patents
Fitusiran לטיפול בהמופיליה a ו-bInfo
- Publication number
- IL317440A IL317440A IL317440A IL31744024A IL317440A IL 317440 A IL317440 A IL 317440A IL 317440 A IL317440 A IL 317440A IL 31744024 A IL31744024 A IL 31744024A IL 317440 A IL317440 A IL 317440A
- Authority
- IL
- Israel
- Prior art keywords
- fitusiran
- hemophilia
- treatment
- Prior art date
Links
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- RUPXJRIDSUCQAN-PQNNUJSWSA-N N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide Chemical compound C[C@@H]1C[C@@H](O)CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O RUPXJRIDSUCQAN-PQNNUJSWSA-N 0.000 title 1
- 229950002735 fitusiran Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263350398P | 2022-06-08 | 2022-06-08 | |
| US202263359695P | 2022-07-08 | 2022-07-08 | |
| US202263382227P | 2022-11-03 | 2022-11-03 | |
| US202263386491P | 2022-12-07 | 2022-12-07 | |
| US202363479337P | 2023-01-10 | 2023-01-10 | |
| US202363483700P | 2023-02-07 | 2023-02-07 | |
| US202363489611P | 2023-03-10 | 2023-03-10 | |
| PCT/US2023/068143 WO2023240199A2 (en) | 2022-06-08 | 2023-06-08 | Treatment of hemophilia with fitusiran |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317440A true IL317440A (he) | 2025-02-01 |
Family
ID=87136472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317440A IL317440A (he) | 2022-06-08 | 2023-06-08 | Fitusiran לטיפול בהמופיליה a ו-b |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240000744A1 (he) |
| EP (1) | EP4536245A2 (he) |
| JP (1) | JP2025519492A (he) |
| KR (1) | KR20250024800A (he) |
| CN (1) | CN119997961A (he) |
| AU (1) | AU2023284452A1 (he) |
| CA (1) | CA3258531A1 (he) |
| IL (1) | IL317440A (he) |
| MX (1) | MX2024015041A (he) |
| TW (1) | TW202417015A (he) |
| WO (1) | WO2023240199A2 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547533A (zh) * | 2024-02-09 | 2025-12-16 | 美商健臻公司 | 用非妥西蘭治療血友病 |
| WO2025212516A1 (en) * | 2024-04-01 | 2025-10-09 | Genzyme Corporation | Treatment of factor x deficiency with fitusiran |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| IL259795B2 (he) | 2015-12-07 | 2024-04-01 | Genzyme Corp | שיטות ותכשירים לטיפול במחלות הקשורות ב– serpinc1 |
| CN111093771A (zh) | 2017-07-10 | 2020-05-01 | 建新公司 | 在患有血友病的受试者中治疗出血事件的方法和组合物 |
| TW202216172A (zh) * | 2020-06-22 | 2022-05-01 | 美商健臻公司 | 治療血友病之方法及組成物 |
-
2023
- 2023-06-08 IL IL317440A patent/IL317440A/he unknown
- 2023-06-08 CA CA3258531A patent/CA3258531A1/en active Pending
- 2023-06-08 KR KR1020257000289A patent/KR20250024800A/ko active Pending
- 2023-06-08 CN CN202380052103.XA patent/CN119997961A/zh active Pending
- 2023-06-08 EP EP23738391.4A patent/EP4536245A2/en active Pending
- 2023-06-08 TW TW112121472A patent/TW202417015A/zh unknown
- 2023-06-08 AU AU2023284452A patent/AU2023284452A1/en active Pending
- 2023-06-08 WO PCT/US2023/068143 patent/WO2023240199A2/en not_active Ceased
- 2023-06-08 JP JP2024572088A patent/JP2025519492A/ja active Pending
- 2023-06-08 US US18/331,748 patent/US20240000744A1/en active Pending
-
2024
- 2024-12-04 MX MX2024015041A patent/MX2024015041A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3258531A1 (en) | 2023-12-14 |
| KR20250024800A (ko) | 2025-02-19 |
| TW202417015A (zh) | 2024-05-01 |
| CN119997961A (zh) | 2025-05-13 |
| WO2023240199A2 (en) | 2023-12-14 |
| WO2023240199A3 (en) | 2024-02-15 |
| EP4536245A2 (en) | 2025-04-16 |
| JP2025519492A (ja) | 2025-06-26 |
| MX2024015041A (es) | 2025-04-02 |
| US20240000744A1 (en) | 2024-01-04 |
| AU2023284452A1 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105158VA (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| GB2590793B (en) | Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy | |
| IL317440A (he) | Fitusiran לטיפול בהמופיליה a ו-b | |
| IL318209A (he) | תרכובות ושיטות רפואיות | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| GB202217355D0 (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| CA219028S (en) | Adhering assembly for medical devices and the like | |
| IL309878A (he) | תרכובות ושיטות טיפוליות | |
| HK40119804A (en) | Fitusiran for the treatment of hemophilia a and b | |
| HUE069672T2 (hu) | Módszer és készülék hulladékok kezelésére | |
| IL317438A (he) | Fitusiran לטיפול בהמופיליה a ו-b במטופלים פדיאטריים | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| IL289069A (he) | אפקט סינרגיסטי של אגוניסט fxr ו- ifn לטיפול בהדבקת hbv | |
| IL312428A (he) | שימוש במאריבאביר לטיפול ולשיטות טיפול שלהן | |
| PT3514235T (pt) | Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento | |
| EP4308146A4 (en) | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES | |
| GB2625512B (en) | Triggered-producer and triggered-consumer instructions | |
| GB202012482D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB2620914B (en) | Waste Treatment | |
| IL308042A (he) | נוגדנים לטיפול ומניעה של covid-19 ושל וריאנטים מתעוררים | |
| CA220514S (en) | Diaper | |
| GB202303287D0 (en) | Therapeutic epitope and uses thereof | |
| HK40118741A (en) | Fitusiran for the treatment of hemophilia a and b in pediatric patients | |
| GB202414155D0 (en) | De-palletiser and palletiser | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions |